Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial

CONTEXT: Abaloparatide is a US Food and Drug Administration-approved parathyroid hormone-related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture. OBJECTIVES: We assessed the cardiovascular safety profile of abaloparatide. DESIGN: Review of heart rate (HR...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosman, Felicia, Peterson, Linda R, Towler, Dwight A, Mitlak, Bruce, Wang, Yamei, Cummings, Steven R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500469/
https://www.ncbi.nlm.nih.gov/pubmed/32658264
http://dx.doi.org/10.1210/clinem/dgaa450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500469/
https://www.ncbi.nlm.nih.gov/pubmed/32658264
http://dx.doi.org/10.1210/clinem/dgaa450

Ejemplares similares